Allergy Shots for Children: Asthma Prevention and Disease Modification

EAACI guidelines recommend a minimum starting age of 5 years for allergy shots. This is a practical guideline based on a child's ability to cooperate during injections and clearly communicate any symptoms during the post-injection observation period — not a hard safety boundary based on immunological evidence. Many 5-year-olds can participate successfully with appropriate preparation and parental support. There is no defined upper age limit for children or adolescents; teenagers follow the same protocols as adults. With Curex at-home SCIT, a parent or caregiver administers each weekly injection after initial Zoom-supervised training — so parental involvement is built into the protocol, which typically supports better observation and adherence compared to solo clinic visits for older children. Some allergists may consider sublingual immunotherapy options for younger children who are not yet ready for injections; discuss with your pediatric allergist.

Yes, a substantial body of evidence suggests allergy shots can reduce the risk of a child with allergic rhinitis developing asthma — a phenomenon called the allergic march. The PAT study, the strongest available evidence, showed that 3 years of SCIT reduced asthma development by roughly half in children with grass or birch pollen rhinoconjunctivitis (OR 2.52 during treatment; OR 2.5 at 10-year follow-up). The number needed to treat is approximately 5-6 children to prevent one asthma case. The EAACI Prevention guideline (Halken et al., 2017) identifies 3-year SCIT or SLIT as the only intervention shown to prevent new asthma development in pollen-allergic children with moderate to severe rhinitis for at least 2 years post-treatment.

Allergy shots for children with dust mite allergy show some of the largest effect sizes in pediatric immunotherapy research. A 2023 meta-analysis by Zheng et al. (Front Pediatr) reported symptom standardized mean difference (SMD) of -1.19 for pediatric HDM SCIT — a clinically substantial effect. Medication use also fell significantly (SMD -1.04). In the HDM-monosensitized pediatric asthma subgroup, FEV1 improved by +5.37% predicted on average. Long-term data show approximately 55% of HDM SCIT patients asymptomatic at 10-year post-treatment follow-up. For dust mite allergy specifically, children have excellent prospects from a complete 3-5 year course of immunotherapy.

Children with mild to moderate, well-controlled allergic asthma can receive allergy shots, and the evidence supports meaningful benefit. However, uncontrolled asthma is the most important contraindication — most guidelines require FEV1 of at least 70% of predicted before each injection. Asthma must be assessed at every visit before administering the injection. The reason is that uncontrolled asthma significantly increases the risk of severe or fatal systemic reactions. The PAT study demonstrates that SCIT in appropriately selected asthmatic children is not only safe but may actually reduce subsequent asthma progression. Your child's allergist and pediatrician should coordinate asthma management alongside the immunotherapy protocol.

Sublingual immunotherapy (SLIT) is a needle-free alternative that is particularly relevant for children, since needle fear is common in this age group. A pediatric meta-analysis by Yang et al. (2023, 50 studies, n=10,813 children) found no significant difference in symptom or medication scores between SLIT and SCIT, but SLIT had 83% fewer treatment-related adverse events (RR 0.17). All four FDA-approved SLIT tablets are approved from age 5 (with Odactra expanded to ages 5-11 in 2025). For children with a single major allergen, SLIT tablets offer comparable efficacy with dramatically better safety and no needles. For polysensitized children needing multi-allergen treatment, Curex at-home SCIT provides a custom-formulated weekly shot without clinic visits — a parent or caregiver administers each dose after Zoom-supervised training, with the prescribing allergist overseeing the entire course. Off-label SLIT drops are another multi-allergen option, though they lack the FDA-approved tablet evidence base.

Children typically need 3-5 years of allergy shots from the first injection to planned discontinuation. The build-up phase takes 3-6 months of weekly or twice-weekly injections, followed by maintenance injections every 2-4 weeks for the remainder of the course. The EAACI 2018 guidelines specify a minimum of 3 years for the disease-modifying effect that persists after stopping. Stopping before 3 years significantly increases relapse risk — the GRASS trial showed 2-year courses do not produce durable post-treatment benefit. Parents often find that starting during elementary school years allows children to complete the full course while still living at home with parental oversight, which tends to support better adherence than starting in adolescence.